Did FPH weightage increase in any Index on 17th sept ? Why it traded such large volumes @ both NZX and ASX ...almost 3 times normal vols ??
Printable View
Did FPH weightage increase in any Index on 17th sept ? Why it traded such large volumes @ both NZX and ASX ...almost 3 times normal vols ??
https://www.covid19treatmentguidelin...d-ventilation/
NIH guidelines regarding HFNC vs CPAP or PPV is totally opposite to new recommendations of NICE ...both cite random studies but NIH studies are peer reviewed also and more in numbers and sample sizes .
Question arises how can two premier medical institutes get totally opposite results from random studies .
NIH states CPAP or NIPPV is most inferior of the 3 options while NICE says its the most superior ...
" High-Flow Nasal Cannula and Noninvasive Positive Pressure Ventilation
HFNC is preferred over NIPPV in patients with acute hypoxemic respiratory failure based on data from an unblinded clinical trial in patients without COVID-19 who had acute hypoxemic respiratory failure. Study participants were randomized to HFNC, conventional oxygen therapy, or NIPPV. The patients in the HFNC group had more ventilator-free days (24 days) than those in the conventional oxygen therapy group (22 days) or NIPPV group (19 days) (P = 0.02), and 90-day mortality was lower in the HFNC group than in either the conventional oxygen therapy group (HR 2.01; 95% CI, 1.01–3.99) or the NIPPV group (HR 2.50; 95% CI, 1.31–4.78).3 In the subgroup of more severely hypoxemic patients (PaO2/FiO2 mm Hg ≤200), the intubation rate was lower for HFNC than for conventional oxygen therapy or NIPPV (HR 2.07 and 2.57, respectively).
The trial’s findings were corroborated by a meta-analysis of eight trials with 1,084 patients conducted to assess the effectiveness of oxygenation strategies prior to intubation. Compared to NIPPV, HFNC reduced the rate of intubation (OR 0.48; 95% CI, 0.31–0.73) and ICU mortality (OR 0.36; 95% CI, 0.20–0.63).4
NIPPV may generate aerosol spread of SARS-CoV-2 and thus increase nosocomial transmission of the infection.5,6 It remains unclear whether HFNC results in a lower risk of nosocomial SARS-CoV-2 transmission than NIPPV. "
Marketwatch today
Shares in Pacific Edge surged 6.1% after it raised $80 million in an oversubscribed placement but the NZX's benchmark equity index fell as its biggest stock, Fisher & Paykel Healthcare, took a 3.1% tumble.
First reaction was it seemed rather strange but I suppose that's the way the market behaves these days
FPH didn't have good August sales ...lowest of FY 22 so far ....only $ 120 Mil estimated from exports data out yesterday .
5 months so far $ 700 Mil ...little above analysts expectations but below mine ...:t_down:
PS : If Sept is also similar then 6 months results can be around $ 825-50 Mil range
With a bit of luck sharetraders will continue to sell down FPH on this news. Share investors, on the other hand , will see it as an opportunity to buy a few more!
:cool:
FPH most sold (Value sells less value buys) by Direct Broking / Jarden clients last week
How right u r !!! Last time SP went below 400 SMA / EMA for a meaningful period was Dec 2018 and it was around $ 12 that time ...We all know what it did in next 2 years ...
Hopefully and likely history will repeat itself as FPH still best quality company on NZX ...so just on that count ...It can be $ 60 in next 2 years ...:t_up:
400 EMA is $31.36 ... still nearly a dollar to go :):
Suspect as well that buyers need to have a bit of patience ... this years financials probably not that flash (compared to the previous).
Agree however - in the long run it likely will be a satisfactory investment.
Mitsubishi bought up about 6.1m shares in the last 4 months.
355654.pdf (nzx-prod-s7fsd7f98s.s3-website-ap-southeast-2.amazonaws.com)